The impact of primary biliary cirrhosis (PBC) on health-related quality of life (HRQOL) is poorly documented. We assessed quality of life in a group of 276 unselected patients with PBC using the Nottingham Health Profile (NHP). This is a generic scale that assesses six major areas commonly associate
The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis
β Scribed by Edward P. Ambinder; Larry B. Cohen; Anita M. Wolke; Steven P. Field; Bernard Adelsberg; Fenton Schaffner; Charles G. Zaroulis
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 404 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Primary biliary cirrhosis (PBC) is a chronic nonsuppurative, destructive cholangitis, whose etiology is unknown. Morbidity arises early from pruritus and later from hypercholesterolemia with xanthoma formation. Therapy is supportive and directed at the complications of cholestasis. Plasmapheresis has been reported to benefit patients with hyperlipidemia and PBC; thus a pilot study of plasmapheresis utilizing the Haemonetics Model 30 with replacement by albumin and saline was conducted. Five patients (four female and one male) with a mean age of 43 (range 29-58) and a mean duration of illness of 9.5 years (range 6-21) with marked jaundice, xanthomas. xanthelasma, hepatomegaly, fatigability, anorexia, and pruritus, as well as mild nausea were studied. Peripheral neuropathy was present in two patients. Two patients had splenomegaly. Two patients had an associated Sjogren syndrome. All patients had high serum bilirubin, alkaline phosphatase, and cholesterol levels and mild elevations in aspartate amino transferase and alanine amino transferase activities. Immune complexes measured in four patients were present. Antimitochondrial antibody titers were significant in all patients. Patients underwent a mean of 63 plasmapheresis procedures over a mean of 112 weeks removing a mean of 94.7 liters of plasma. No serious toxicity was seen.
All patients showed a reduction in pruritus, xanthomas, xanthelasnias, and serum cholesterol values. The two patients who had evidence of Sjogren syndrome noted subjective improvement. All patients who had fatigue. anorexia and nausea also noted moderate improvement. There was no change in hepatomegaly or splenomegaly in patients demonstrating such organomegaly . Liver function did not change significantly. Overall, four patients had improvement in their condition and one patient achieved stability. We strongly recommend the use of chronic plasmapheresis for patients with PBC who have failed more "conventional" regimens.
π SIMILAR VOLUMES
The article by Jackson et al. 1 and accompanying editorial by Corpechot and Poupon 2 have raised the interesting question of practice variation in the diagnosis and treatment of primary biliary cirrhosis (PBC). In general, the variable use of effective medical therapies continues to be linked with t
Primary biliary cirrhosis (PBC) is generally a slowly progressive disease that may lead to cirrhosis and liver failure. However, patients with PBC often suffer from a variety of symptoms long before the development of cirrhosis that include issues of daily living that have an impact on their work en
Primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome is a clinical entity characterized by the occurrence of both conditions at the same time in the same patient. In addition to PBC-AIH overlap syndrome, transitions from one autoimmune disease to another have been reported, bu
develop thrombocytopenia of various causes, e.g., decreased controls for the indirect and direct MAIPA assay, respectively, and production, increased turnover or splenic ''pooling.'' were obtained from healthy donors of blood group AB. The specificity of the antibodies was further determined by the
We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer